ImmunityBio a annoncé lundi le lancement de ResQ215B, une étude clinique de phase 2 évaluant la thérapie cellulaire CD19 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results